Brief: Tonix Pharmaceuticals And Makana Therapeutics Announce Collaboration Combining Tonix’S Anti-Cd40l Monoclonal Antibody (Tnx-1500) With Makana’S Genetically Engineered Organs In Preclinical And Clinical Xenotransplantation Studies

Tonix Pharmaceuticals Holding

09/04/2025 12:02

April 9 (Reuters) - Tonix Pharmaceuticals Holding Corp TNXP.O:

TONIX PHARMACEUTICALS AND MAKANA THERAPEUTICS ANNOUNCE COLLABORATION COMBINING TONIX’S ANTI-CD40L MONOCLONAL ANTIBODY (TNX-1500) WITH MAKANA’S GENETICALLY ENGINEERED ORGANS IN PRECLINICAL AND CLINICAL XENOTRANSPLANTATION STUDIES

Source text: ID:nGNX1M5DQ8

Further company coverage: TNXP.O

 (((( Reuters.briefs@thomsonreuters.com ;));))